Ownership Capital B.V. Has $107.66 Million Stock Holdings in Bio-Techne Co. (NASDAQ:TECH)

Ownership Capital B.V. reduced its position in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) by 21.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,395,246 shares of the biotechnology company's stock after selling 391,027 shares during the quarter. Bio-Techne comprises 2.4% of Ownership Capital B.V.'s portfolio, making the stock its 19th largest holding. Ownership Capital B.V. owned about 0.88% of Bio-Techne worth $107,657,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. bought a new position in Bio-Techne during the 3rd quarter valued at $27,000. CVA Family Office LLC bought a new stake in shares of Bio-Techne during the 4th quarter worth $31,000. GAMMA Investing LLC bought a new stake in shares of Bio-Techne during the 4th quarter worth $44,000. Federated Hermes Inc. bought a new stake in shares of Bio-Techne during the 3rd quarter worth $47,000. Finally, Clear Street Markets LLC boosted its stake in shares of Bio-Techne by 255.8% during the 3rd quarter. Clear Street Markets LLC now owns 733 shares of the biotechnology company's stock worth $50,000 after acquiring an additional 527 shares in the last quarter. 98.95% of the stock is owned by institutional investors.

Insider Buying and Selling at Bio-Techne

In other Bio-Techne news, Director Roeland Nusse sold 10,400 shares of the firm's stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $76.98, for a total transaction of $800,592.00. Following the transaction, the director now directly owns 43,097 shares in the company, valued at $3,317,607.06. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 4.45% of the company's stock.

Bio-Techne Stock Up 2.2 %

Shares of NASDAQ:TECH traded up $1.40 during midday trading on Friday, hitting $64.06. 973,784 shares of the stock were exchanged, compared to its average volume of 917,625. The company has a debt-to-equity ratio of 0.23, a quick ratio of 3.03 and a current ratio of 4.37. Bio-Techne Co. has a 52-week low of $51.79 and a 52-week high of $89.91. The business's fifty day simple moving average is $69.82 and its two-hundred day simple moving average is $68.48. The company has a market capitalization of $10.07 billion, a PE ratio of 46.42, a P/E/G ratio of 7.80 and a beta of 1.22.

Bio-Techne (NASDAQ:TECH - Get Free Report) last announced its quarterly earnings data on Thursday, February 1st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by ($0.03). Bio-Techne had a return on equity of 14.21% and a net margin of 19.58%. The firm had revenue of $272.60 million for the quarter, compared to analysts' expectations of $277.48 million. As a group, research analysts predict that Bio-Techne Co. will post 1.52 earnings per share for the current fiscal year.

Bio-Techne Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 26th. Investors of record on Monday, February 12th were issued a dividend of $0.08 per share. The ex-dividend date was Friday, February 9th. This represents a $0.32 annualized dividend and a dividend yield of 0.50%. Bio-Techne's dividend payout ratio is 23.19%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Scotiabank assumed coverage on Bio-Techne in a research note on Thursday, February 8th. They set a "sector outperform" rating and a $80.00 price objective for the company. Deutsche Bank Aktiengesellschaft reduced their price objective on Bio-Techne from $85.00 to $82.00 and set a "buy" rating for the company in a research note on Thursday, April 18th. Stifel Nicolaus lowered Bio-Techne from a "buy" rating to a "hold" rating and set a $65.00 target price for the company. in a report on Friday, February 2nd. Royal Bank of Canada reduced their target price on Bio-Techne from $85.00 to $75.00 and set a "sector perform" rating for the company in a report on Friday, February 2nd. Finally, Stephens reduced their target price on Bio-Techne from $92.00 to $87.00 and set an "overweight" rating for the company in a report on Friday, February 2nd. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $83.90.

Bio-Techne Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.